Japan’s Takara Bio Submits Clinical Trial Notification To PMDA For Leukemia Gene Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan-based Takara Bio submitted a clinical trial notification to Japan's Pharmaceutical and Medical Device Agency for TBI-0301, a gene therapy to treat leukemia. TBI-0301 is a retroviral vector to be used in donor lymphocyte transfusion to treat relapsed leukemia and to stabilize side effects caused by immune reactions from donor lymphocytes. (Click here for more - Japanese language)